EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Cardiovascular disease in transgendered people: A review of the literature and discussion of risk

Leighton J Seal iD

JRSM Cardiovascular Disease · 2019-01 · 8

DOI: 10.1177/2048004019880745 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift JRSM Cardiovascular Disease, online erschienen am 30.09.2019. Verfasst von Leighton J Seal. Beteiligte Einrichtung: St George's Hospital Medical School, London, UK. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This review examines the impact of gender affirming hormone therapy used in the transgendered and non-binary populations on cardiovascular outcomes and surrogate markers of cardiovascular health. Current evidence suggests that hormonal therapy for transgendered women decreases or is neutral regarding myocardial infarction risk. There is an increased incidence of venous thromboembolism (VTE), but newer studies suggest that the risk is significantly lower than previously described. For transgendered men, there appears to be an adverse effect on lipid parameters but this does not translate into an increased risk of cardiovascular disease above that of general male population. In all transgendered people, risk factor interventions such as smoking cessation, weight management and treatment of co-morbid conditions are important in optimising cardiovascular health. The effect of gender affirming hormonal therapy in transgendered people is difficult to interpret due to the variety of hormone regimens used, the relative brevity of the periods of observation and the influence of confounding factors such as the historical use of less physiological, oestrogens such as conjugated equine oestrogen and ethinylestradiol which are more pro-thrombotic than the 17β oestradiol that is used in modern practice.

Schlagwörter

Stichwörter der Autor:innen

Transgender mancardiovascular riskhormone replacement therapytransgender woman

Autor:innen und Institutionen

  • St George's Hospital Medical School, London, UK.
  • St George's University Hospitals NHS Foundation Trust, London, UK.
  • Gender Identity Clinic, Tavistock and Portman NHS Foundation Trust, London, UK.

ORCID-Profile: Leighton J Seal

Zitieren

APA

Seal, L. J. (2019). Cardiovascular disease in transgendered people: A review of the literature and discussion of risk. JRSM Cardiovascular Disease, 8. https://doi.org/10.1177/2048004019880745

Vancouver

Seal LJ. Cardiovascular disease in transgendered people: A review of the literature and discussion of risk. JRSM Cardiovascular Disease. 2019;8. doi:10.1177/2048004019880745

BibTeX
@article{Seal2019,
  author = {Seal, Leighton J},
  title = {Cardiovascular disease in transgendered people: A review of the literature and discussion of risk},
  journal = {JRSM Cardiovascular Disease},
  year = {2019},
  volume = {8},
  doi = {10.1177/2048004019880745}
}
Kostenlos starten →